2-(2-fluorophenyl)-4,5-dihydrooxazole | 156060-97-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-fluorophenyl)-4,5-dihydrooxazole
• 英文别名: 2-Fluoro-1-(4,5-dihydrooxazol-2-yl)benzene；2-(2-fluorophenyl)-4,5-dihydro-1,3-oxazole
• CAS: 156060-97-8
• 化学式: C₉H₈FNO
• 分子量: 165.167
• InChiKey: WGNQXOOZRSACBQ-UHFFFAOYSA-N

物化性质

• 沸点：
  256.3±23.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-fluorophenyl)-4,5-dihydrooxazole 在 palladium on activated charcoal nickel(IV) oxide 、 正丁基锂 、 氢气 作用下， 以 甲醇 、 苯 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 49.5h， 生成 1-(2-oxazol-2-ylphenyl)piperazine
  参考文献：
  名称：

  N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α₁-Adrenoceptor Antagonists

  摘要：

  Novel arylpiperazines were identified as alpha(1)-adrenoceptor(BR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides,;as well as carboxamides of quinoline, I,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta;a were used as a ''negative screen'' for the test antagonists. Binding to alpha(1)-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g, 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the alpha(1)-AR subtype prevalent in the human lower urinary tract (pA(2) values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the alpha(1D)-AR.

  DOI：

  10.1021/jm970166j
• 作为产物：
  描述：

  2-fluoro-N-(2-hydroxyethyl)benzamide 在 三苯基膦 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 二氯甲烷 为溶剂， 生成 2-(2-fluorophenyl)-4,5-dihydrooxazole
  参考文献：
  名称：

  多氟芳基恶唑啉的选择性钯催化的CF活化/碳-碳键形成

  摘要：

  描述了通过邻位CF活化对多氟苯基恶唑啉的选择性钯催化的Suzuki-Miyaura偶联反应。发现以DPPF作为配体的反应发生得比与其他配体的反应快得多。在反应条件下可以耐受各种芳基硼酸，包括具有挑战性的官能化芳基硼酸，例如可烯醇化的酮，醛，氰基，酯和三氟甲基。

  DOI：

  10.1021/jo2023262

文献信息

• \x9b3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine,
  申请人：Syntex (U.S.A.) Inc.

  公开号：US05688795A1

  公开（公告）日：1997-11-18

  The present invention relates to novel .alpha..sub.1 -adrenoceptor antagonists of Formula I: ##STR1## in which: p is 0 or 1; t is 0, 1 or 2; X is O, S or NR.sup.6 (in which R.sup.6 is hydro or (C.sub.1-6)alkyl); Y and Z are independently CH or N; R.sup.1 is hydro, hydroxy, halo, nitro, amino, cyano, (C.sub.1-4)alkylthio, acetylamino, trifluoroacetylamino, methylsulfonylamino, (C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl, (C.sub.3-6)cycloalkyl (C.sub.1-4)alkyl, oxazol-2-yl, aryl, heteroaryl, aryl (C.sub.1-4)alkyl, heteroaryl (C.sub.1-4)alkyl, (C.sub.1-6)alkyloxy, (C.sub.3-6)cycloalkyloxy, (C.sub.3-6)cycloalkyl (C.sub.1-4)alkyloxy, 2-propynyloxy, aryloxy, heteroaryloxy, aryl (C.sub.1-4)alkyloxy or heteroaryl (C.sub.1-4)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms and aryl or heteroaryl is optionally substituted with one to two substituents independently selected from halo and cyano); R.sup.2 is hydro, hydroxy, halo, cyano, (C.sub.1-6)alkyl or (C.sub.1-6)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms); R.sup.3 is -C (O)R.sup.7 (wherein R.sup.7 is (C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl, di(C.sub.1-4)alkylamino, N-(C.sub.1-4)alkyl-N-(C.sub.1-4)alkyloxyamino, (C.sub.1-4)alkyl((C.sub.1-4)alkyloxy)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or piperazin-1-yl); R.sup.4 is halo, hydroxy, cyano, (C.sub.1-6)alkyl or (C.sub.1-6)alkyloxy; and R.sup.5 is (C.sub.1-6)alkyl; and the pharmaceutically acceptable salts and N-oxides thereof.

  本发明涉及以下式I的新型α1-肾上腺素受体拮抗剂：##STR1## 其中：p为0或1；t为0, 1或2；X为O、S或NR.sup.6（其中R.sup.6为羟基或（C.sub.1-6）烷基）；Y和Z独立地为CH或N；R.sup.1为羟基、羟基、卤素、硝基、氨基、氰基、（C.sub.1-4）烷基硫基、乙酰氨基、三氟乙酰氨基、甲磺酰氨基、（C.sub.1-6）烷基、（C.sub.3-6）环烷基、（C.sub.3-6）环烷基（C.sub.1-4）烷基、噁唑-2-基、芳基、杂环芳基、芳基（C.sub.1-4）烷基、杂环芳基（C.sub.1-4）烷基、（C.sub.1-6）烷氧基、（C.sub.3-6）环烷氧基、（C.sub.3-6）环烷基（C.sub.1-4）烷氧基、2-丙炔氧基、芳氧基、杂环芳氧基、芳基（C.sub.1-4）烷氧基或杂环芳基（C.sub.1-4）烷氧基（其中烷基可选择性地用1至3个卤原子取代，芳基或杂环芳基可选择性地用1至2个独立选择的卤素和氰基取代）；R.sup.2为羟基、羟基、卤素、氰基、（C.sub.1-6）烷基或（C.sub.1-6）烷氧基（其中烷基可选择性地用1至3个卤原子取代）；R.sup.3为-C（O）R.sup.7（其中R.sup.7为（C.sub.1-6）烷基、（C.sub.3-6）环烷基、二（C.sub.1-4）烷基氨基、N-（C.sub.1-4）烷基-N-（C.sub.1-4）烷氧基氨基、（C.sub.1-4）烷基（（C.sub.1-4）烷氧基）氨基、吡咯烷-1-基、哌啶-1-基、吗啉-4-基或哌嗪-1-基）；R.sup.4为卤素、羟基、氰基、（C.sub.1-6）烷基或（C.sub.1-6）烷氧基；R.sup.5为（C.sub.1-6）烷基；以及其药学上可接受的盐和N-氧化物。
• Sequential <i>meta</i>-/<i>ortho</i>-C–H Functionalizations by One-Pot Ruthenium(II/III) Catalysis
  作者：Korkit Korvorapun、Nikolaos Kaplaneris、Torben Rogge、Svenja Warratz、A. Claudia Stückl、Lutz Ackermann

  DOI：10.1021/acscatal.7b03648

  日期：2018.2.2

  Sequential twofold meta-C–H/ortho-C–H functionalization was achieved by means of versatile ruthenium(II) biscarboxylate catalysis. The double C–H activation proved viable in a one-pot fashion with the assistance of synthetically useful imidates. The operationally simple twofold C–H functionalization occurred with high levels of positional selectivity control and was conducted in a nonsequential manner

  顺序双重元-C–H /邻位-C–H官能化是通过多官能钌（II）双羧酸钌催化实现的。在合成有用的酰亚胺的帮助下，一氧化碳的双重活化被证明是一锅法可行的。操作简单的双重C–H官能化在高水平的位置选择性控制下发生，是通过明智地选择反应温度以非顺序方式进行的。详细的实验机理研究，包括空前的电子顺磁共振（EPR）实验，为均相C–X键断裂和便捷的C–H钌化提供了有力的支持，而计算密度泛函理论（DFT）分析则为涉及以下方面的新型机理提供了支持通过环金属化钌（III）配合物作为关键中间体的协同催化。
• Pyrimidinedione, pyrimidinetrione, triazinedione and
  申请人：Syntex (U.S.A.) Inc.

  公开号：US05859014A1

  公开（公告）日：1999-01-12

  Compounds of Formula I: ##STR1## where R.sup.5 is a group selected from Formulae (a), (b), (c) and (d): ##STR2## and the pharmaceutically acceptable salts and N-oxides thereof, are .alpha..sub.1 -adrenergic receptor antagonists useful for the treatment of diseases involving directly or indirectly an obstruction of the lower urinary tract, such as benign prostatic hyperplasia.

  化合物的化学式I：##STR1##其中R.sup.5是从式(a)、(b)、(c)和(d)中选择的基团：##STR2##以及其药用可接受的盐和N-氧化物，是用于治疗涉及直接或间接阻塞下尿道的疾病，如良性前列腺增生的α1-肾上腺素受体拮抗剂。
• Preparation of chiral phosphorus, sulfur and selenium containing 2-aryloxazolines
  作者：Markus Peer、Johannes C. de Jong、Matthias Kiefer、Thomas Langer、Heiko Rieck、Heico Schell、Peter Sennhenn、Jürgen Sprinz、Henning Steinhagen、Burkhard Wiese、Günter Helmchen

  DOI：10.1016/0040-4020(96)00267-0

  日期：1996.5

  synthetic amino alcohols. For oxazoline formation three procedures were employed: (i) one pot condensation with a 2-halobenzoic acid, (ii) ZnCl2 catalyzed condensation with a 2-halobenzonit-rile, and (iii) a three step sequence via a 2-halobenzamide and a tosylate or chloride. Phosphinooxazolines containing stereogenic phosphorus were prepared by either diastereoselective nucleophilic substitution of halogenide

  由市售或合成的氨基醇制备一系列对映体纯的2- [2-（二芳基膦基）芳基]-恶唑啉。对于恶唑啉的形成，采用了三种程序：（i）与2-卤代苯甲酸一锅缩合，（ii）ZnCl 2与2-卤代苯甲腈-苯胺催化缩合，和（iii）通过2-卤代苯甲酰胺的三步顺序和甲苯磺酸盐或氯化物。通过非对映选择性亲核取代Ar 1 Ar 2 PC1的卤化物或通过LiPAr 1 Ar 2亲核芳族取代制备含有立体异构磷的膦恶唑啉。另外，制备了硫和硒类似物。
• Oxazolinyl-Assisted Ru(II)-Catalyzed C–H Allylation with Allyl Alcohols and Synthesis of 4-Methyleneisochroman-1-ones
  作者：Diksha Singh、Gangam Srikanth Kumar、Manmohan Kapur

  DOI：10.1021/acs.joc.9b01536

  日期：2019.10.18

  for C-H allylation of aryl oxazolines using allylic alcohols as the coupling partner. The present transformation unravels the unusual reactivity of allylic alcohols in the synthesis of 4-methyleneisochroman-1-ones and C-H-allylated products. A complete switch in the product selectivity was observed with substrate control and tuning the reaction conditions. The approach employs allyl alcohols as an efficient

  我们在本文中报道了使用烯丙醇作为偶联伙伴的芳基恶唑啉的CH烯丙基化的钌催化的，恶唑啉定向的策略。本转化揭示了在4-亚甲基异色满-1-酮和CH-烯丙基化产物的合成中烯丙基醇的异常反应性。通过底物控制和调节反应条件，观察到产物选择性的完全改变。该方法采用烯丙醇作为预活化的烯丙基化剂的有效替代品，以高度选择性的方式获得各种产品。